{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-052109","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.347094+00:00","generated_at":"2026-06-03T00:15:47.896453+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kura Oncology Q1 net loss $49.5M, cash $527M; ziftomenib gets BTD for NPM1-mutant AML","bullets":["Net loss of $49.5M in Q1 2024 vs $34.1M in Q1 2023; cash $527M provides runway into 2027.","FDA granted Breakthrough Therapy Designation to ziftomenib for relapsed/refractory NPM1-mutant AML based on KOMET-001 data.","Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment of 85 patients by mid-2024.","Positive preliminary combo data: 100% CR rate in newly diagnosed with ziftomenib + 7+3; 53% ORR in R/R with venetoclax/azacitidine.","First patient dosed with KO-2806 + cabozantinib in RCC; on track to dose with adagrasib in KRASG12C NSCLC by mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-052109","json":"https://secwatch.observer/filing/0000950170-24-052109.json","markdown":"https://secwatch.observer/filing/0000950170-24-052109.md","text":"https://secwatch.observer/filing/0000950170-24-052109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000095017024052109/0000950170-24-052109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000095017024052109/kura-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:15:47.896453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d621363361ef35082a73404f9029541f3513c7c0","claim":"Kura Oncology, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $49.5 million.","evidence_excerpt":"Kura Oncology, Inc. (the \"Company\") issued a press release announcing the Company's financial results for the first quarter ended March 31, 2024 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017024052109/0000950170-24-052109-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the first quarter of 2024 was $49.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}